- Home
- EDTK vs ABVC Comparison
EDTK vs ABVC Comparison
Compare EDTK & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- ABVC
- Stock Information
- Founded
- EDTK 2013
- ABVC 2015
- Country
- EDTK China
- ABVC United States
- Employees
- EDTK N/A
- ABVC N/A
- Industry
- EDTK Other Consumer Services
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- ABVC Health Care
- Exchange
- EDTK Nasdaq
- ABVC Nasdaq
- Market Cap
- EDTK 15.7M
- ABVC 16.7M
- IPO Year
- EDTK 2020
- ABVC N/A
- Fundamental
- Price
- EDTK $1.04
- ABVC $0.88
- Analyst Decision
- EDTK
- ABVC
- Analyst Count
- EDTK 0
- ABVC 0
- Target Price
- EDTK N/A
- ABVC N/A
- AVG Volume (30 Days)
- EDTK 6.0K
- ABVC 648.3K
- Earning Date
- EDTK 05-02-2025
- ABVC 04-15-2025
- Dividend Yield
- EDTK N/A
- ABVC N/A
- EPS Growth
- EDTK N/A
- ABVC N/A
- EPS
- EDTK N/A
- ABVC N/A
- Revenue
- EDTK $624,365.00
- ABVC $509,588.00
- Revenue This Year
- EDTK N/A
- ABVC $735.18
- Revenue Next Year
- EDTK N/A
- ABVC N/A
- P/E Ratio
- EDTK N/A
- ABVC N/A
- Revenue Growth
- EDTK N/A
- ABVC 234.31
- 52 Week Low
- EDTK $0.84
- ABVC $0.40
- 52 Week High
- EDTK $1.27
- ABVC $1.73
- Technical
- Relative Strength Index (RSI)
- EDTK 57.61
- ABVC 51.34
- Support Level
- EDTK $0.94
- ABVC $0.82
- Resistance Level
- EDTK $1.06
- ABVC $1.00
- Average True Range (ATR)
- EDTK 0.05
- ABVC 0.17
- MACD
- EDTK 0.00
- ABVC -0.02
- Stochastic Oscillator
- EDTK 74.19
- ABVC 23.31
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.